FAHD2A, one of the three mammalian FAH domain-containing proteins, has its exact function yet to be fully elucidated. FAH domain-containing proteins in both prokaryotes and eukaryotes carry out diverse enzymatic reactions related to the structure of their FAH domains [2].

In bioinformatics-based research on the causal relationship between obesity and hepatocellular carcinoma (HCC), FAHD2A was identified as one of the four differentially expressed genes common in obesity and HCC. Functional enrichment analyses indicated its potential roles in processes such as RNA capping, viral transcription, IL-17 signaling, and endocrine resistance. These genes also exhibited negative correlations with immune cell infiltration and immunotherapy markers in HCC, suggesting that they may be implicated in obesity-induced hepatocarcinogenesis through regulating cell cycle, inflammation, and immune evasion [1].

Additionally, in a study on stratifying the malignant risk of intraductal papillary mucinous neoplasm of the pancreas, FAHD2A was identified as one of the five discriminatory biomarkers with large LASSO coefficients and an AUC > 0.75 [3].

In conclusion, FAHD2A appears to be involved in multiple biological processes relevant to diseases such as HCC and pancreatic neoplasms. The findings from these studies help in understanding its role in disease-related mechanisms, potentially providing insights for further research on disease prevention and treatment.